stockportfolio.pro
Autolus Therapeutics plc (AUTL)
Healthcare · Biotechnology · NasdaqGS
Autolus Therapeutics plc revenue & earnings — last 5 fiscal years
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $6.19M | $1.70M | $10.12M | $75.39M |
| Gross profit | — | — | $1.70M | $-1.27M | $-20.98M |
| Net income | $-142.10M | $-148.84M | $-208.38M | $-220.66M | $-287.53M |
| Net margin | — | -2403.0% | -12272.3% | -2180.5% | -381.4% |
Source: Autolus Therapeutics plc SEC filings (10-K).
Explore 5 years of Autolus Therapeutics plc financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track AUTL in your portfolio →
Autolus Therapeutics plc financial history by metric
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Autolus Therapeutics plc — frequently asked questions
What is Autolus Therapeutics plc's revenue?
Autolus Therapeutics plc (AUTL) reported revenue of $75.39M for fiscal year 2025, up 644.9% from the prior year, according to its SEC filings.
Is Autolus Therapeutics plc profitable?
No — AUTL reported a net loss of $-287.53M in fiscal 2025.
What is AUTL's P/E ratio?
Autolus Therapeutics plc trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Autolus Therapeutics plc have?
As of fiscal year 2025, AUTL carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Autolus Therapeutics plc's gross margin?
AUTL's gross margin was -27.8% in fiscal 2025 — gross profit of $-20.98M on revenue of $75.39M.
What is Autolus Therapeutics plc's market cap?
Autolus Therapeutics plc (AUTL) has a market capitalization of about $411.19M, based on the latest data in our nightly-refreshed cache.
When does Autolus Therapeutics plc's fiscal year end?
AUTL's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Autolus Therapeutics plc's official SEC filings (10-K and 10-Q), covering 5 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.